New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 28, 2014
07:05 EDTALIMAlimera Sciences and STA sign deal to distribute ILUVIEN in Oceania
Australian and New Zealand patients suffering from vision impairment due to a type of diabetes-induced eye disease will have access to a new treatment, following a license deal between Australian biopharmaceutical company Specialised Therapeutics Australia, or STA, and Alimera Sciences. The exclusive agreement enables STA to distribute ILUVIEN, a sustained release intravitreal implant used to treat vision impairment associated with chronic diabetic macular oedema, when the condition is deemed insufficiently responsive to current available therapies.
News For ALIM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 21, 2015
07:37 EDTALIMAlimera Sciences signs exclusive agreement for distribution of Iluvien in Canada
Alimera Sciences announced that it has signed an exclusive agreement with Knight Therapeutics, a leading Canadian specialty pharmaceutical company, for the distribution in Canada of ILUVIEN, Alimera's sustained release intravitreal implant for the treatment of diabetic macular edema. Under the terms of this agreement, Knight will also handle all regulatory and commercial activities for ILUVIEN in Canada. ILUVIEN currently is not approved for sale in Canada.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use